Cartesian Therapeutics (RNAC) Stock Price, News & Analysis

Company Overview

Cartesian Therapeutics is a clinical-stage biotechnology company specializing in the development of next-generation cell and gene therapies using a proprietary messenger RNA (mRNA) platform. The company’s core technology enables precise, nonviral delivery of mRNA to patient-derived immune cells, allowing for customized engineering of T cells and other immune effectors. Cartesian’s approach is designed to accelerate manufacturing timelines, reduce production complexity and enhance safety profiles compared with conventional viral vector–based methods.

The company’s pipeline includes multiple investigational programs targeting hematologic malignancies and solid tumors. Cartesian’s lead candidates are engineered T-cell therapies that coexpress tumor-targeting receptors and immune-modulating payloads, with preclinical data demonstrating potent anti-tumor activity. In addition to oncology applications, Cartesian is evaluating its mRNA delivery platform for therapeutic areas such as autoimmune disorders and rare genetic diseases, leveraging modular design principles to address diverse disease targets.

Founded in 2018 as a spin-out from leading academic research institutions, Cartesian Therapeutics is headquartered in Cambridge, Massachusetts, with research collaborations and manufacturing partnerships across North America and Europe. Since its inception, the company has established cGMP-compliant manufacturing capacity to support clinical supply and is working closely with contract development and manufacturing organizations (CDMOs) to scale its operations in preparation for late-stage trials.

Cartesian’s leadership team comprises industry veterans in cell and gene therapy development, mRNA biology, regulatory affairs and commercial strategy. The executive suite is led by a Chief Executive Officer with over two decades of experience in biologics innovation, supported by a Chief Scientific Officer renowned for contributions to RNA engineering. The company’s board of directors includes experts in clinical development, manufacturing and patient advocacy, reflecting Cartesian’s commitment to advancing transformational therapies from bench to bedside.

Key Stats

• Today's Range: $13.33 to $14.37
• 50-Day Range: $8.77 to $13.77
• 52-Week Range: $8.46 to $26.50
• Volume: 96,376 shs
• Average Volume: 99,692 shs
• Market Capitalization: $351.36 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.00
• Consensus Rating: Moderate Buy

Cartesian Therapeutics Stock Analysis - MarketRank™

Cartesian Therapeutics scored higher than 41% of companies evaluated by MarketBeat, and ranked 615th out of 925 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Cartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Cartesian Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cartesian Therapeutics are expected to decrease in the coming year, from $4.56 to ($3.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cartesian Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cartesian Therapeutics is -0.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

31.65% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cartesian Therapeutics does not currently pay a dividend.

Dividend Growth

Cartesian Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

31.65% of the float of Cartesian Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Cartesian Therapeutics has a short interest ratio ("days to cover") of 31, which indicates bearish sentiment.

Change versus previous month

Short interest in Cartesian Therapeutics has recently increased by 3.14%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.59

News Sentiment

Cartesian Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Cartesian Therapeutics this week, compared to 3 articles on an average week.

Search Interest

2 people have searched for RNAC on MarketBeat in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

60.30% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

RNAC Stock Analysis - Frequently Asked Questions

How have RNAC shares performed this year?

Cartesian Therapeutics' stock was trading at $17.91 at the beginning of 2025. Since then, RNAC shares have decreased by 24.4% and is now trading at $13.54.

How were Cartesian Therapeutics' earnings last quarter?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) released its quarterly earnings results on Thursday, May, 8th. The company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.61) by $0.07. The firm had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.69 million.

When did Cartesian Therapeutics' stock split?

Cartesian Therapeutics shares reverse split on Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

How do I buy shares of Cartesian Therapeutics?

Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cartesian Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNAC
• Previous Symbol: NASDAQ:RNAC
• CIK: 1453687
• Web: selectabio.com
• Phone: 617-923-1400
• Fax: 617-924-3454
• Employees: 64
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Cartesian Therapeutics: $40.00
• High Price Target: $42.00
• Low Price Target: $38.00
• Potential Upside/Downside: +195.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($52.83)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 2.97
• P/E Growth: N/A
• Net Income: -$77.42 million
• Net Margins: N/A
• Pretax Margin: -111.27%
• Return on Equity: N/A
• Return on Assets: -7.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 12.34
• Quick Ratio: 12.34

Sales & Book Value

• Annual Sales: $38.91 million
• Price / Sales: 9.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.27) per share
• Price / Book: -50.15

Miscellaneous

• Outstanding Shares: 25,950,000
• Free Float: 10,304,000
• Market Cap: $351.36 million
• Optionable: Optionable
• Beta: 0.36